Evidence map›Paper›PMID 39721917›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Mitochondrial-targeted therapies in traumatic brain injury: From bench to bedside.

Sidra Tabassum, Silin Wu, Chang-Hun Lee, Bosco Seong Kyu Yang, Aaron M Gusdon, Huimahn A Choi, Xuefang S Ren

Abstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. The Role of MRI in Debunking the Fallacy of "Mild" Traumatic Brain Injury.Journal of magnetic resonance imaging : JMRI · 2026
    Review
  11. Review
  12. Article
  13. Black gas, bright future: HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  14. Applications of Hydrogels in Emergency Therapy.Gels (Basel, Switzerland) · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Advancing neurocritical care: Bridging molecular mechanisms and physiological monitoring to neurotherapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sidra TabassumNovel Treatments for Acute Brain Injury Institute, Texas Medical Center, TX, USA; Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Silin WuNovel Treatments for Acute Brain Injury Institute, Texas Medical Center, TX, USA; Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Chang-Hun LeeDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Republic of Korea.
Bosco Seong Kyu YangNovel Treatments for Acute Brain Injury Institute, Texas Medical Center, TX, USA; Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Aaron M GusdonNovel Treatments for Acute Brain Injury Institute, Texas Medical Center, TX, USA; Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Huimahn A ChoiNovel Treatments for Acute Brain Injury Institute, Texas Medical Center, TX, USA; Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Xuefang S RenNovel Treatments for Acute Brain Injury Institute, Texas Medical Center, TX, USA; Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA. Electronic address: Xuefang.ren@uth.tmc.edu.

Funding

A Novel Blood Substitution Approach Treats Acute Ischemia in the Aged BrainRF1AG073659 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI REN, XUEFANG SOPHIE · 2025 to 2025
$2.5M
MicroRNAs, Mitochondria and the Blood-Brain Barrier - Therapeutic Targets for StrokeR01NS117606 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Xuefang Sophie Ren · 2023 to 2026
$1.8M
Radiographic markers and therapeutic targets of cerebral edema after SAHR01NS131469 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Huimahn Alex Choi · 2024 to 2026
$1.7M
Discovery of Plasma Biomarkers of Delayed Cerebral Ischemia after Subarachnoid HemorrhageR61NS119640 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHOI, HUIMAHN ALEX, SAVARRAJ, JUDE PJ · 2022 to 2024
$1.6M
Metabolic alterations after aneurysmal subarachnoid hemorrhageK23NS121628 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Aaron Mark Gusdon · 2022 to 2026
$924k
A Novel Blood Substitution Approach Treats Acute Ischemia in the Aged BrainR01AG073659 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI REN, XUEFANG SOPHIE · 2024 to 2024
$645k
NIA NIH HHS R01 AG073659NIA NIH HHS RF1 AG073659NINDS NIH HHS K23 NS121628NINDS NIH HHS R01 NS117606NINDS NIH HHS R01 NS131469NINDS NIH HHS R61 NS119640
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a leading cause of morbidity and mortality worldwide, with limited effective therapeutic options currently available. Recent research has highlighted the pivotal role of mitochondrial dysfunction in the pathophysiology of TBI, making mitochondria an attractive target for therapeutic intervention. This review comprehensively examines advancements in mitochondrial-targeted therapies for TBI, bridging the gap from basic research to clinical applications. We discuss the underlying mechanisms of mitochondrial damage in TBI, including oxidative stress, impaired bioenergetics, mitochondrial dynamics, and apoptotic pathways. Furthermore, we highlight the complex interplay between mitochondrial dysfunction, inflammation, and blood-brain barrier (BBB) integrity, elucidating how these interactions exacerbate injury and impede recovery. We also evaluate various preclinical studies exploring pharmacological agents, gene therapy, and novel drug delivery systems designed to protect and restore mitochondrial function. Clinical trials and their outcomes are assessed to evaluate the translational potential of mitochondrial-targeted therapies in TBI. By integrating findings from bench to bedside, this review emphasizes promising therapeutic avenues and addresses remaining challenges. It also provides guidance for future research to pave the way for innovative treatments that improve patient outcomes in TBI.

Indexed as

Brain Injuries, TraumaticMitochondriaNeuroprotective AgentsTranslational Research, BiomedicalAnimalsBlood-Brain BarrierDrug Delivery SystemsGenetic TherapyHumansOxidative StressNeuroprotective AgentsMitochondrial dysfunctionNovel drug delivery systemTherapeutic interventionsTraumatic brain injury

Identifiers

PMID39721917
PMCPMC11840356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.